Medical Prognosis Institute A/S – Passing of Annual General Meeting



Hoersholm; April 24.  2014 – On Thursday 24 April 2014 at 4.30 p.m., the annual general meeting of Medical Prognosis Institute A/S was held with the following agenda:
 
  1. Election of the Chairman of the annual general meeting
  2. The board of directors’ report on the company’s activities during the past year
  3. Motion from the board of directors to prepare and present the annual report only in English
  4. Presentation of the annual accounts with the auditors’ report for adoption
  5. Resolution on appropriation of profits or payment of loss in accordance with the adopted annual accounts
  6. Election of the board of directors
  7. Appointment of auditor
  8. Motion from the board of directors to increase in cash the company’s share capital at the market price by minimum nominally DKK 50,000 and maximum nominally DKK 84,000 from nominally DKK 951,372 to a total of minimum nominally DKK 1,001,372 and maximum nominally DKK 1,035,372 by a direct placement without any pre-emption right to existing shareholders, including a motion to amend the company’s Articles of Association accordingly.
  9. Motion from the board of directors to adopt a new authorisation to issue warrants and any relating capital increases, including a motion to amend the company’s Articles of Association accordingly.
  10. Authorisation to the chairman of the annual general meeting
  11. Any other business
 
Re item 1
In accordance with article 10.2 of the company’s articles of association, the board of directors appointed Attorney-at-Law Thomas Holst Laursen to chair the annual general meeting.
 
Re item 2
The general meeting adopted the report of the board of directors.
 
Re item 3
The proposal by the board of directors to prepare and present the annual report of the company in English only was approved by the general meeting, and a provision in this respect was incorporated in the company’s articles of association.
 
Re item 4
The general meeting adopted the 2013 annual accounts.
 
Re item 5
The general meeting approved the proposed payment of loss in accordance with the adopted annual accounts.
 
Re item 6
Jørgen Søberg Petersen, Niels Johansen, Peter Buhl and Steen Meier Knudsen were re-elected to the board of directors, and Magnus Persson was elected as a new member of the board of directors.
 
Re item 7
The general meeting re-elected PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab as the company’s auditor.
 
Re item 8
The general meeting approved the proposal to increase in cash the company’s share capital at the market price by minimum nominally DKK 50,000 and maximum nominally DKK 84,000 from nominally DKK 951,372 to a total of minimum nominally DKK 1,001,372 and maximum nominally DKK 1,035,372 by a direct placement without any pre-emption right to existing shareholders as well as the proposal to amend the company’s articles of association in accordance therewith.
 
Re item 9
The general meeting authorised the board of directors – in the period until 24 April 2019 – to decide once or several times to issue warrants to subscribe for shares of up to nominally DKK 95,000 and to decide on the relating capital increase. The warrants may be issued to the company’s key employees, members of the board of directors and any other key figures. In connection therewith, the general meeting resolved to incorporate the authorisation in the company’s articles of association.
 
Re item 10
The general meeting authorised the chairman of the general meeting to register the resolutions with the Danish Business Authority.
 
 
For further information please contact
Peter Buhl Jensen, CEO
E-mail: [email protected]
Cell Phone: (+45) 21 60 89 22
 
Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark

Sign up for press releases and receive relevant information about Allarity Therapeutics A/S